Iqymune

Human Normal Immunoglobulin, the active ingredient in Iqymune, is an immunoglobulin presented as a solution for injection for intravenous use. It treats primary and secondary immunodeficiency diseases, Kawasaki disease, and immune thrombocytopenic purpura in appropriate patients.

GNH USA supplies Iqymune as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Iqymune is an intravenous immunoglobulin used to replace deficient antibodies in various immune‑mediated conditions. - Primary immunodeficiency diseases: restores IgG levels to reduce infection frequency. - Secondary immunodeficiency: provides passive immunity when the patient’s own antibody production is compromised. - Kawasaki disease: helps reduce coronary artery complications by modulating inflammation. - Immune thrombocytopenic purpura (ITP): raises platelet counts through immune modulation.

Adverse reactions can occur with any intravenous immunoglobulin product.

Common Side Effects: - Headache: mild to moderate, often transient. - Fever or chills: typical infusion‑related response. - Nausea or vomiting: gastrointestinal upset during or after infusion. - Fatigue: feeling of tiredness post‑infusion. - Myalgia: muscle aches that resolve within days. - Hypertension or hypotension: blood pressure fluctuations during infusion.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Thromboembolic events: clot formation in veins or arteries. - Acute renal failure: especially with high‑dose or rapid infusion. - Aseptic meningitis: severe headache with meningeal signs. - Hemolysis: destruction of red blood cells leading to anemia. - Transfusion‑related acute lung injury (TRALI): respiratory distress shortly after infusion.

Before administering Iqymune, consider the following safety measures. - Screen for IgA deficiency: patients with anti‑IgA antibodies are at higher risk of anaphylaxis. - Monitor renal function: ensure adequate hydration and avoid nephrotoxic co‑medications. - Assess thrombotic risk: evaluate history of clotting disorders before high‑dose infusions. - Observe for infusion reactions: start at a slower rate and watch for signs of hypersensitivity. - Contraindicate in known severe allergic reactions to immunoglobulin products. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Intravenous immunoglobulin can affect the activity or safety of several co‑administered drugs.

Major Interactions (Avoid): - Live attenuated vaccines: may reduce vaccine efficacy and increase infection risk. - Cytotoxic chemotherapy agents: can amplify immunosuppression and toxicity. - High‑dose steroids: may mask signs of infection during therapy.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may alter INR and increase bleeding risk. - Diuretics: combined use can heighten renal impairment. - ACE inhibitors: potential for additive hypotensive effects during infusion.